ArticleBMC biochemistry2006
Phosphorylation-facilitated sumoylation of MEF2C negatively regulates its transcriptional activity.
Article in BMC biochemistry, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 81 citations in OpenAlex.
- The Diverse Roles of the MEF2 Transcription Factor Family in Tumor Progression and Emerging Therapeutic Opportunities.Biomedicines · 2026Review
- Pre- and Postsynaptic MEF2C Promotes Experience-Dependent, Input-Specific Development of Cortical Layer 4 to Layer 2/3 Excitatory Synapses and Regulates Activity-Dependent Expression of Synaptic Cell Adhesion Molecules.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2024Article
- Identification of a novel MEF2C::SS18L1 fusion in childhood acute B-lymphoblastic leukemia.Journal of cancer research and clinical oncology · 2024Article
- MEF2C Hypofunction in Neuronal and Neuroimmune Populations Produces MEF2C Haploinsufficiency Syndrome-like Behaviors in Mice.Biological psychiatry · 2020Article
- Article
- The role of SUMOylation during development.Biochemical Society transactions · 2020Review
- Emerging roles for MEF2 in brain development and mental disorders.Current opinion in neurobiology · 2019Review
- Zebrafish Vestigial Like Family Member 4b Is Required for Valvulogenesis Through Sequestration of Transcription Factor Myocyte Enhancer Factor 2c.Frontiers in cell and developmental biology · 2019Article
- MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia.Cancer discovery · 2018Article
- Review
- MEF2C Interacts With c-FOS in PTH-Stimulated Mmp13 Gene Expression in Osteoblastic Cells.Endocrinology · 2017Article
- SUMOylation and calcium signalling: potential roles in the brain and beyond.Neuronal signaling · 2017Review
- Review
- Sumoylation in Synaptic Function and Dysfunction.Frontiers in synaptic neuroscience · 2016Review
- Neuronal SUMOylation: mechanisms, physiology, and roles in neuronal dysfunction.Physiological reviews · 2014Review
- Myocyte enhancer factor 2C in hematopoiesis and leukemia.Oncogene · 2014Review
- Receptor trafficking and the regulation of synaptic plasticity by SUMO.Neuromolecular medicine · 2013Review
- Protein sumoylation in brain development, neuronal morphology and spinogenesis.Neuromolecular medicine · 2013Review
- MEF2B mutations lead to deregulated expression of the oncogene BCL6 in diffuse large B cell lymphoma.Nature immunology · 2013Article
- Neurotoxin-induced selective ubiquitination and regulation of MEF2A isoform in neuronal stress response.Journal of neurochemistry · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundSumoylation has emerged as an important posttranslational regulatory mechanism for transcription factors and cofactors. Sumoylation of many transcription factors represses their transcriptional activities. The myocyte enhancer factor 2 (MEF2) family of transcription factors plays an important role in regulating gene expression during myogenesis and has been recently shown to be sumoylated.
resultsConsistent with earlier reports, we show that sumoylation of MEF2C at K391 inhibits its transcriptional activity. Sumoylation of MEF2C does not block its DNA-binding activity. A small C-terminal fragment of MEF2C containing K391, referred to as delta-N2-MEF2C, is efficiently sumoylated and, when targeted to DNA, represses transcription at neighbouring promoters. Because delta-N2-MEF2C lacks the binding site for class II histone deacetylases (HDACs), this result suggests that sumoylation of MEF2C may help to recruit transcriptional repressors other than these HDACs. Intriguingly, we show that phosphorylation of S396 in MEF2C, a residue in close proximity to the major sumoylation site (K391) and known to be phosphorylated in vivo, enhances sumoylation of delta- N2-MEF2C in vitro. The S396A mutation reduces sumoylation of MEF2C in vivo and enhances the transcription activity of MEF2C in reporter assays.
conclusionWe propose that phosphorylation of MEF2C at S396 facilitates its sumoylation at K391, which in turn recruits yet unidentified co-repressors to inhibit transcription. Our studies further suggest that sumoylation motifs containing a phosphorylated serine or an acidic residue at the +5 position might be more efficiently sumoylated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.